Welcome to our dedicated page for IDEXX LABORATORIES /DE SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEXX LABORATORIES /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEXX LABORATORIES /DE's regulatory disclosures and financial reporting.
IDEXX Laboratories, Inc. presents its preliminary 2026 Proxy Statement summarizing 2025 performance, corporate priorities and governance matters.
The company reports $4.3B revenue, $13.08 diluted EPS, 10% reported revenue growth and highlights innovation milestones and a planned CEO transition effective upon adjournment of the 2026 Annual Meeting on May 12, 2026.
IDEXX Laboratories executive Sharon E. Underberg, EVP, GC & Corporate Secretary, exercised an incentive stock option on March 3, 2026. The option conversion resulted in 197 shares of common stock at a transaction price of 505.5300 per share, bringing her direct common stock holdings to 7,137.654 shares.
The incentive stock option right-to-buy covered 197 shares and, following the exercise, showed 0 derivative shares remaining. A footnote states the option grant to buy issuer common stock vested on February 14, 2026, indicating this was a scheduled equity award exercise.
IDEXX Laboratories Executive Vice President Nimrata Hunt sold 1,758 shares of common stock in an open-market transaction on March 3, 2026 at a weighted average price of $634.5718 per share. After this sale, Hunt directly held 18,140.944 shares and indirectly held 160 shares jointly with a spouse.
According to a footnote, the weighted average sale price reflects individual trades executed between $634.5301 and $634.8201 per share.
IDEXX Laboratories Executive Vice President Michael G. Erickson reported corrected equity awards and updated holdings. The amended filing states that on February 12, 2026 he received a non‑qualified stock option for 13,667 shares and an incentive stock option for 162 shares, both with an exercise price equal to that day’s closing stock price.
The non‑qualified option vests in four annual installments beginning February 14, 2027, while the incentive stock option becomes exercisable in a single installment on February 14, 2030. The amendment clarifies that previously reported grants of 6,319 restricted stock units did not occur, and notes his common stock holdings include 184 vested but deferred restricted stock units.
IDEXX Laboratories reported a proposed sale of 1,758 common shares via Form 144, listed with Morgan Stanley Smith Barney LLC as the broker on 03/03/2026.
The shares are labeled as exercised shares with an exercise date of 08/06/2025. The excerpt also shows prior sales of 2,693 common shares on 02/25/2026 with an aggregate dollar amount of 1,781,530.72.
IDEXX Laboratories President and CEO Jonathan Jay Mazelsky exercised stock options for 23,523 shares of common stock at exercise prices of $141.6000 and $505.5300. He then sold 23,326 shares in multiple open-market trades at prices including $650.6695 and $663.0439, ending with 83,803.302 shares held directly.
IDEXX Laboratories Executive Vice President Nimrata Hunt reported an open-market sale of common stock. On February 26, 2026, Hunt sold 2,693 shares at a weighted average price of $661.5413 per share in open-market transactions. After the sale, Hunt directly owned 19,898.944 common shares and indirectly owned 160 shares jointly with a spouse. A footnote explains that the sale prices ranged from $661.35 to $661.8275 per share, with detailed trade breakdowns available upon request.
IDEXX Laboratories, Inc. files its Annual Report describing a diversified diagnostics business focused on companion animal health, water quality, and livestock, poultry and dairy testing, plus a smaller human point-of-care line. The company highlights extensive use of AI across analyzers, imaging and software, and a cloud ecosystem that connects in-clinic instruments with reference labs and telemedicine.
IDEXX reports $251.2 million of 2025 research and development expense, or 5.8% of consolidated revenue, up from $219.8 million (5.6%) in 2024 and $191.0 million (5.2%) in 2023. It notes significant regulatory oversight globally, reliance on some sole‑source suppliers, increasing PFAS and AI regulation, and strong human‑capital programs supporting about 11,000 employees in 34 countries.